arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

ArriVent BioPharma, Inc.

AVBP Health Care Biotechnology: Pharmaceutical Preparations
$18.60
▼ -2.7% Today
as of Oct 23, 11:15 ET
Last 30 days -35.53% Sep 14 → Oct 23
$13.87 $18.29 $22.70 $27.12 $31.54 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$18.93
High
$19.68
Low
$18.78
Volume
$843,600
Avg Vol
$629,446
Mkt Cap
$1.4B
P/E (TTM)
—
Beta
—
52w High
$35.83
52w Low
$11.36
Div Yield
—
Shares Out
$48M

Recent Press Releases & News last 60 days · 10 items

Oct 19 · 12:01 PR GlobeNewswire
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
Oct 12 · 20:58 MT Newswires
ArriVent BioPharma Doses First Patient in Phase 1 Trial of ARR-002 for Ovarian, Endometrial Cancer
Oct 12 · 20:01 PR GlobeNewswire
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
▸ Show all 10 press releases & news Free account →

AVBP earnings at a glance

The options market is pricing a move of about ±16.1% after the report, a range of roughly $15.60 to $21.60 from today's $18.60. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±1.2% on average; after the most recent report on May 11, 2026 it moved -1.6%. That means options currently expect more movement than AVBP has typically delivered. AVBP beat the consensus EPS estimate in 0 of its last 4 reported quarters. Implied volatility is currently 137%. The share price of $18.60 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$11
$36
30% of range
Avg surprise (last 4)
-58.0%
Avg reaction (last 2)
-1.2%
0% positive
Latest IV / EM
137%
EM ±16.1% · $18 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-10.79$-8.24$-5.70$-3.15$-0.61 Actual $-9.45Actual $-10.79Actual $-5.52Actual $-0.70Actual $-0.65Actual $-0.61Actual $-1.90Est $-0.66Actual $-0.90Est $-0.70Actual $-0.83Est $-0.78Actual $-0.96Est $-0.88Actual $-1.05 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-64M$-54M$-43M$-32M$-22M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.05 — — — — financials
Mon May 11, 2026Mar/2026 $-0.96 $-0.88 -9.1% +49.5% -1.6% earnings
Mon Nov 10, 2025Sep/2025 $-0.83 $-0.78 -6.4% — — earnings
Mon Aug 11, 2025Jun/2025 $-0.90 $-0.70 -28.6% — — earnings
Mon May 12, 2025Mar/2025 $-1.90 $-0.66 -187.9% — -0.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.61 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.65 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.70 — — — — financials
Sat Sep 30, 2023Sep 2023 $-5.52 — — — — financials
Fri Jun 30, 2023Jun 2023 $-10.79 — — — — financials
Fri Mar 31, 2023Mar 2023 $-9.45 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-53M$-46M—$-38M$-34M$-67M—$-24M
Net income$-50M$-43M—$-35M$-31M$-64M—$-21M
EPS (diluted)$-1.05$-0.96—$-0.83$-0.90$-1.90—$-0.61

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$155M$62M$46M$113M$113M$50M$74M$283M
Inventory————————
Total current assets$394M$349M$333M$321M$250M$186M$227M$292M
Total assets$395M$349M$333M$327M$270M$215M$275M$293M
Long-term debt————————
Total liabilities$28M$25M$26M$22M$20M$13M$17M$15M
Total equity$367M$324M$307M$305M$250M$203M$258M$277M

Implied volatility — last 90 days

90%195%300%405%510% Jun 07 — IV 114% · EM ±15.7%Jun 08 — IV 136% · EM ±18.0%Jun 09 — IV 153% · EM ±19.1%Jun 10 — IV 147% · EM ±17.4%Jun 11 — IV 120% · EM ±13.2%Jun 12 — IV 122% · EM ±12.4%Jun 15 — IV 196% · EM ±14.2%Jun 16 — IV 114% · EM ±6.8%Jun 17 — IV 275% · EM ±11.5%Jun 19 — IV 126% · EM ±27.9%Jun 22 — IV 143% · EM ±29.8%Jun 23 — IV 144% · EM ±29.5%Jun 24 — IV 157% · EM ±31.4%Jun 25 — IV 155% · EM ±30.5%Jun 26 — IV 190% · EM ±36.3%Jun 29 — IV 183% · EM ±32.4%Jun 30 — IV 158% · EM ±27.2%Jul 01 — IV 127% · EM ±21.2%Jul 02 — IV 154% · EM ±24.9%Jul 03 — IV 160% · EM ±24.9%Jul 06 — IV 148% · EM ±20.4%Jul 07 — IV 140% · EM ±18.5%Jul 08 — IV 166% · EM ±20.8%Jul 09 — IV 145% · EM ±17.2%Jul 10 — IV 154% · EM ±17.1%Jul 13 — IV 170% · EM ±14.2%Jul 14 — IV 255% · EM ±18.4%Jul 15 — IV 242% · EM ±14.3%Jul 16 — IV 471% · EM ±19.7%Jul 20 — IV 151% · EM ±35.6%Jul 21 — IV 154% · EM ±35.8%Jul 22 — IV 144% · EM ±33.0%Jul 23 — IV 148% · EM ±33.4%Jul 24 — IV 152% · EM ±33.6%Jul 27 — IV 163% · EM ±34.0%Jul 28 — IV 163% · EM ±33.4%Jul 29 — IV 155% · EM ±31.0%Jul 30 — IV 162% · EM ±31.7%Jul 31 — IV 159% · EM ±30.3%Aug 03 — IV 174% · EM ±30.9%Aug 04 — IV 119% · EM ±20.5%Aug 05 — IV 124% · EM ±20.7%Aug 06 — IV 122% · EM ±19.8%Aug 07 — IV 134% · EM ±21.0%Aug 10 — IV 134% · EM ±18.6%Aug 11 — IV 134% · EM ±17.7%Aug 12 — IV 146% · EM ±18.3%Aug 13 — IV 138% · EM ±16.2%Aug 14 — IV 112% · EM ±12.4%Aug 17 — IV 169% · EM ±14.1%Aug 18 — IV 100% · EM ±7.2%Aug 19 — IV 158% · EM ±9.3%Aug 24 — IV 90% · EM ±18.8%Aug 25 — IV 101% · EM ±20.7%Aug 26 — IV 114% · EM ±22.9%Aug 27 — IV 112% · EM ±22.0%Aug 28 — IV 113% · EM ±21.6%Aug 31 — IV 117% · EM ±20.8%Sep 01 — IV 124% · EM ±21.4%Sep 02 — IV 123% · EM ±20.6%Sep 03 — IV 134% · EM ±21.7%Sep 04 — IV 148% · EM ±23.2%Sep 07 — IV 167% · EM ±23.2%Sep 08 — IV 114% · EM ±15.0%Sep 09 — IV 165% · EM ±20.6%Sep 10 — IV 149% · EM ±17.6%Sep 11 — IV 169% · EM ±18.6%Sep 14 — IV 260% · EM ±21.7%Sep 15 — IV 313% · EM ±22.6%Sep 16 — IV 459% · EM ±27.1%Sep 17 — IV 511% · EM ±21.3%Sep 21 — IV 129% · EM ±27.0%Sep 22 — IV 131% · EM ±26.7%Sep 23 — IV 142% · EM ±28.4%Sep 24 — IV 149% · EM ±29.2%Sep 25 — IV 145% · EM ±27.8%Sep 28 — IV 166% · EM ±29.4%Sep 29 — IV 161% · EM ±27.8%Sep 30 — IV 141% · EM ±23.5%Oct 01 — IV 167% · EM ±27.0%Oct 02 — IV 166% · EM ±26.0%Oct 06 — IV 130% · EM ±17.2%Oct 07 — IV 116% · EM ±14.5%Oct 08 — IV 137% · EM ±16.1%

Sector peers

GHRS
GH Research PLC
$1.4B $17.76-6.1%
TYRA
Tyra Biosciences, Inc.
$1.4B $20.40-1.0%
RARE
Ultragenyx Pharmaceutical Inc.
$1.5B $15.66-1.6%
SNDX
Syndax Pharmaceuticals, Inc.
$1.5B $13.35+1.5%
PAHC
Phibro Animal Health Corporation
$1.5B $39.14-0.3%
ORIC
Oric Pharmaceuticals, Inc.
$1.3B $13.00-6.1%

AVBP earnings FAQ

What is AVBP's expected move for earnings?

Options currently price a move of about ±16.1%, or $3.00 per share either way from $18.60.

How does AVBP stock usually react to earnings?

Across the last 2 reports the average next-day move was ±1.2%, up 0 times and down 2 times.

What is AVBP's implied volatility?

AVBP's at-the-money implied volatility is about 137% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in